BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15481315)

  • 1. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease.
    Koutroubakis IE; Malliaraki N; Dimoulios PD; Karmiris K; Castanas E; Kouroumalis EA
    Dig Dis Sci; 2004 Sep; 49(9):1433-7. PubMed ID: 15481315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Voudouri T; Kouroumalis EA
    Inflamm Bowel Dis; 2006 Feb; 12(2):100-5. PubMed ID: 16432373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonenzymatic Serum Antioxidant Capacity in IBD and Its Association with the Severity of Bowel Inflammation and Corticosteroids Treatment.
    Neubauer K; Kempinski R; Matusiewicz M; Bednarz-Misa I; Krzystek-Korpacka M
    Medicina (Kaunas); 2019 Apr; 55(4):. PubMed ID: 30986917
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
    Ciećko-Michalska I; Fedak D; Mach T
    Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased serum fetuin-A levels and active inflammatory bowel disease.
    Ma P; Feng YC
    Am J Med Sci; 2014 Jul; 348(1):47-51. PubMed ID: 24487480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease.
    Kapsoritakis AN; Kapsoritaki AI; Davidi IP; Lotis VD; Manolakis AC; Mylonis PI; Theodoridou AT; Germenis AE; Potamianos SP
    BMC Gastroenterol; 2008 Nov; 8():55. PubMed ID: 19036126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8
    Dai SX; Gu HX; Lin QY; Huang SZ; Xing TS; Zhang QF; Wu G; Chen MH; Tan WE; Jian HJ; Zheng ZW; Zhong T; Zhang MH; Cheng XF; Huang P; Liao GJ; Sha WH
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):693-702. PubMed ID: 28502591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
    Solem CA; Loftus EV; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
    Inflamm Bowel Dis; 2005 Aug; 11(8):707-12. PubMed ID: 16043984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease.
    Koutroubakis IE; Drygiannakis D; Karmiris K; Drygiannakis I; Makreas S; Kouroumalis EA
    Dig Dis Sci; 2005 Dec; 50(12):2330-4. PubMed ID: 16416183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
    Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
    J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
    Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
    PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease.
    D'Odorico A; Bortolan S; Cardin R; D'Inca' R; Martines D; Ferronato A; Sturniolo GC
    Scand J Gastroenterol; 2001 Dec; 36(12):1289-94. PubMed ID: 11761019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with primary biliary cirrhosis have increased serum total antioxidant capacity measured with the crocin bleaching assay.
    Notas G; Miliaraki N; Kampa M; Dimoulios F; Matrella E; Hatzidakis A; Castanas E; Kouroumalis E
    World J Gastroenterol; 2005 Jul; 11(27):4194-8. PubMed ID: 16015688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced formation of advanced oxidation protein products in IBD.
    Krzystek-Korpacka M; Neubauer K; Berdowska I; Boehm D; Zielinski B; Petryszyn P; Terlecki G; Paradowski L; Gamian A
    Inflamm Bowel Dis; 2008 Jun; 14(6):794-802. PubMed ID: 18213700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases.
    Nikolaus S; Schulte B; Al-Massad N; Thieme F; Schulte DM; Bethge J; Rehman A; Tran F; Aden K; Häsler R; Moll N; Schütze G; Schwarz MJ; Waetzig GH; Rosenstiel P; Krawczak M; Szymczak S; Schreiber S
    Gastroenterology; 2017 Dec; 153(6):1504-1516.e2. PubMed ID: 28827067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
    Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases?
    Kaplan M; Yuksel M; Ates I; Kilic ZM; Kilic H; Kuzu UB; Kayacetin E
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1120-5. PubMed ID: 26642816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases.
    Korkmaz H; Asıl M; Temel T; Öztürk B; Kebapçılar L
    Turk J Med Sci; 2021 Oct; 51(5):2403-2412. PubMed ID: 33984894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
    Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
    World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.